221194-50-9

Upstream product

• 100-39-0 benzyl bromide 
• 107-21-1 ethylene glycol 
• 459-46-1 4-Fluorobenzyl bromide 
• 459-57-4 4-fluorobenzaldehyde 
• 66822-17-1 4-(1,3-dioxolan-2-yl)fluorobenzene 

Downstream Products

• 221194-64-5 methanesulfonic acid 2-(4-fluoro-benzyloxy)-ethyl ester 
• 103061-52-5 1-{[(2-bromoethyl)oxy]methyl}-4-fluorobenzene 
• 103061-24-1 6-(4-fluorobenzyloxy)-2,2-dimethyl-4-[1,2,4]triazol-1-yl-hexan-3-one 
• 1434277-31-2 1-(3,3-dimethylcycloprop-1-en-1-yl)-2-[(4-fluorophenyl)methoxy]ethanol 
• 66822-17-1 4-(1,3-dioxolan-2-yl)fluorobenzene 

Relevant academic research and scientific papers

SUBSTITUTED INDAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS

The present invention relates to substituted indazole compounds which modulate the activity of protein kinases and are therefore useful in treating diseases caused by degulated protein kinase activity, like cancer. The present invention also provides methods for preparing these compounds, pharmaceutical compositions comprising these compounds, and methods of treating diseases utilizing such these compounds or the pharmaceutical compositions containing them.

Highly efficient stereoselective catalytic C(sp3)-H insertions with donor rhodium carbenoids generated from cyclopropenes

Rings of five and six: Donor alkenyl rhodium carbenoids generated from 3,3-dimethylcyclopropenylcarbinols exhibit high reactivity in intramolecular C-H insertions. The reactions proceed under remarkably mild conditions, tolerate the presence of the free hydroxy group, and afford an efficient and stereoselective access to a variety of functionalized carbocycles and oxygen heterocycles. Copyright

Triazole Compounds, Use Thereof and Agents Containing Same

The present invention relates to compounds of the formula I in which the variables have the meanings defined in the claims and in the description.

Discovery of novel 1-azoniabicyclo[2.2.2]octane muscarinic acetylcholine receptor antagonists

A novel 4-hydroxyl(diphenyl)methyl substituted quinuclidine series was discovered as a very promising class of muscarinic antagonists. The structure-activity relationships of the connectivity of the diphenyl moiety to the quinuclidine core and around the ring nitrogen side chain are described. Computational docking studies using an homology model of the M3 receptor readily explained the observed structure-activity relationship of the various compounds. Compound 14o was identified as a very potent, slowly reversible M3 antagonist with a very long in vivo duration of bronchoprotection.

Muscarinic acetylcholine receptor antagonists

Muscarinic Acetylcholine Receptor Antagonists and methods of using them are provided.

NOVEL OXABISPIDINE COMPOUNDS AND THEIR USE IN THE TREATMENT OF CARDIAC ARRHYTHMIAS

There is provided compounds of formula (I), wherein R1, R2, R3, R4, R 41 to R46, A, B and G have meanings given in the description, which are useful in the prophylaxis and in the treatment of arrhythmias, in particular atrial and ventricular arrhythmias.